Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSGO-EC-9501: adjuvant radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma
2004-002429-37Phase 4Active
- Sponsor
- Nordic Society of Gynaecological Oncology
- Start
- Oct 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of doxorubicin, cisplatin, paclitaxel, carboplatin, epirubicin and 1 more in endometrial cancer (EC) (2 arms), sponsored by Nordic Society of Gynaecological Oncology. Primary endpoint: Overall survival. Started Oct 2004; status: active.
02
Drugs
doxorubicincisplatinpaclitaxelcarboplatinepirubicin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2004-002429-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002429-37.